HomeHealthcareAtrial Fibrillation Market Analysis By Procedure (Pharmacological Drugs, Anti-arrhythmic, Anti-coagulant, Non-Pharmacological Treatments, Radiofrequency, HIFU, Cryoablation, Microwave, Laser, Catheter Ablation, Maze Surgery, Electric Cardioversion) And Segment Forecasts To 2020

Atrial Fibrillation Market Analysis By Procedure (Pharmacological Drugs, Anti-arrhythmic, Anti-coagulant, Non-Pharmacological Treatments, Radiofrequency, HIFU, Cryoablation, Microwave, Laser, Catheter Ablation, Maze Surgery, Electric Cardioversion) And Segment Forecasts To 2020

Published: July 2014 | Report Code: GVR6

Report Summary Table of Contents Segmentation Methodology Request Sample

 

Industry Insights

Atrial fibrillation (AF) is a type of cardiac arrhythmia which is caused by irregular electrical activities in the atria. It may occur with no symptoms but most common ones associated with it are fainting, palpitations, congestive failure of the heart or chest pain. The confirmation for AF is obtained by an electrocardiogram which exhibits an absence of the P wave and irregular rate of ventricular contractions. These irregularities in the regular cardio-electric impulses of sino-atrial node are the result of interference from chaotic electric impulses generating from roots of pulmonary veins consequently leading to conduction of an irregular heartbeat. Atrial fibrillation on the basis of the severity of the condition is divided into three types namely paroxysmal (symptoms stop within 24 hours), persistent (symptoms continue for more than a week) and permanent (long term) atrial fibrillation. According to WHO, atrial fibrillation is the most common type of arrhythmia. Rising incidence rates of atrial fibrillation triggering diseases such as mitral stenosis, hyperthyroidism, high blood pressure, pulmonary embolus, pneumonia and obesity is one of the most significant factors responsible for the high prevalence of this disorder. In patients suffering from AF, the risk of a blood clot forming in the heart and causing a stroke is increased to almost five times than others. With the presence of other above mentioned disorders may increase this risk even further. The general methods of treatment of AF include medications to slow down the heart rate to bring it to a standard sinus rhythm, the use of electrical cardioversions synchronized with the sinoatrial node or surgical cardiac ablations using catheter based procedures to prevent the recurrence. To control the risk of blood clot formation and prevent the occurrence of strokes, patients of AF are also required to be treated with blood thinning and anti-clotting medications. These although decrease the risk of a stroke considerably, but in the process greatly increase risks of internal bleeding, mainly among older patients. The prevalence of AF in a population increases with age. According to WHO, 8% of people over the age of 80 suffer with some form of atrial fibrillation. Chronic AF leads to a small increase in the risk of death. Consequently, the most important factor driving this market is the global aging population combined with the changes in lifestyle increasing the risks of obesity and high blood pressure. Some of the other key factors for the growth of this market include the growing need for minimally invasive procedures, smaller cardiac incisions and faster post-surgical recovery times.

Procedure Insights

The market for atrial fibrillation is segmented on the basis of pharmacological and non-pharmacological procedures for its treatment. The pharmacological treatments include anti-arrhythmic and anti-coagulant drugs and the procedures such as catheter ablation, maze surgery and electric cardioversion. Surgical catheter ablation includes various procedures of which the most commonly used are radiofrequency and microwave catheter ablation. The reduced size of the cardiac incision and faster recovery from these procedures are the main reasons for their increased application. 

Regional Insights

Key regions for the said market researched upon in the study include North America, Europe, Asia Pacific and RoW. North America dominated the overall market in terms of share in 2013 owing to the presence of high procedure volumes supported by the presence of sophisticated healthcare infrastructure, high patient awareness and healthcare expenditure levels.

Competitive Insights

Key players of this market include Sanofi Aventis, Biosense Webster Inc., AtriCure Inc., CardioFocus Inc., Boston Scientific Corporation, Bristol-Myers Squibb Corporation, Endoscopic Technologies Inc., St. Jude Medical Inc., Johnson & Johnson Ltd. and Boehringer Ingelheim GmbH. St. Jude Medical Inc. has developed an innovative Endosense’s TactiCath which is able to provide live feedback about applied pressure during radiofrequency and microwave catheter ablations. With the increase in the application of these procedures, it is expected that TactiCath will also witness a growth in demand.

Key questions answered by the report 

  • What was the size of the atrial fibrillation market in 2013; what are the expected growth trends and market forecast for 2014 to 2020
  • Which companies were the leaders in 2013, what are their current products and what are the strategic initiatives taken by them
  • What opportunities are available to these and other contenders in this space
  • What are the barriers and opportunities in the atrial fibrillation market?
  • Which were the top-performing procedure segments in 2013? How will these segments perform in 2020
  • Which were the top-performing regional markets in 2013? How will these markets perform in 2020
 
arrowGo to Table of Contents arrowGo to Segmentation arrowGo to Methodology arrowRequest Sample
 
 
Choose License Type:




Customize This Report
Get this report customized and tailored to meet your research needs. For specific research requirements please click here

Need Research Assistance
Call us or write to us
Phone:  1-415-349-0058
Toll Free:  1-888-202-9519
Email: sales@grandviewresearch.com